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Abstract
Background Pharmacists are increasingly involved in patient care. This new role in a complex healthcare system with 
demanding patients may lead to moral dilemmas. There has been little research into pharmacy ethics, and existing data are 
limited by their retrospective nature and small sample sizes. A thematic overview of the moral dilemmas experienced by 
community pharmacists is still missing. Objective To make a thematic overview of moral dilemmas experienced in daily 
pharmacy practice. Setting Dutch community pharmacy. Methods Dutch community pharmacists wrote a narrative about a 
moral dilemma they had experienced in clinical practice. The narratives were analysed using qualitative content analysis to 
identify underlying themes. Main outcome measure Themes of moral dilemmas. Results Twenty-two themes were identified 
in 128 narratives. These moral dilemmas arose predominantly during pharmacists’ contact with patients and other health pro-
fessionals. The relationship between the pharmacist, patient and other health professionals was complicated by other parties, 
such as legal representatives, health insurance companies, and regulators. Conclusion The moral dilemmas experienced by 
community pharmacists are more diverse than previously reported. The main dilemmas arose in their professional contacts, 
frequently when their professional autonomy was challenged by the behaviour of patients and other health professionals.
Keywords Community pharmacists · Moral dilemmas · Netherlands · Pharmacy ethics
Impact on practice
• The moral dilemmas for pharmacists are diverse, but 
underlying is often a troubled relationship with physi-
cians and/or patients that hampers the pharmacist to 
deliver appropriate pharmaceutical care.
• Reflection on moral dilemmas may help community 
pharmacists to strengthen their professional autonomy.
• Investing in good professional relationships with other 
health professionals and in a therapeutic relationship with 
patients may benefit recognition of pharmacists’ exper-
tise.
Introduction
 Worldwide, the primary focus of pharmacists is shift-
ing from products to patients [1–7]. This patient-centred 
approach means that pharmacists have to identify patients’ 
concerns and needs, and collaborate closely with other 
health professionals in order to ensure effective and safe 
use of medicines [8]. Lastly, pharmacists are responsible 
for helping patients to achieve definite health outcomes.
Nowadays, health professionals such as pharmacists are 
faced with ever more regulations, financial pressure, and 
increased competition. At the same time, the demand for 
health services is growing as a result of population ageing, 
more chronic illnesses, and increased healthcare consum-
erism [9, 10]. Economic and legal constraints and demand-
ing patients challenge health professionals’ autonomy 
to act in the best interests of society and the individual 
patient [9, 11–19]. In this complex setting, pharmacists 
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are frequently confronted with moral dilemmas [20–30] 
arising from conflicting personal, professional, institu-
tional or societal values of the different parties involved 
[28, 31–33].
These moral dilemmas need to be studied in order to 
address the challenges pharmacists face in their professional 
role [24, 29, 30, 34–39].
There have been few international studies of the moral 
dilemmas experienced by community pharmacists, and 
existing studies vary widely in aim, method and presenta-
tion of results [24–27, 29, 30, 40]. In most existing studies, 
pharmacists were presented with scenarios of moral dilem-
mas and their moral reasoning was assessed. Pharmacists 
found it difficult to recall moral dilemmas and most studies 
interviewed a limited number of pharmacists [20–23, 30, 
41]. Hence the themes of moral dilemmas experienced in 
clinical practice may still be incomplete.
Aim of the study
We aimed to make a thematic overview of moral dilem-
mas community pharmacists actually experienced in clinical 
practice.
Ethics approval
The Medical Ethics Review Committee of the University 
Medical Centre Leiden concluded that the Dutch Medi-
cal Research Involving Human Subjects Act (WMO) was 
not applicable. All participants consented that their narra-
tives could be used for the purpose of the study. Data that 
could give clues about the origin of dilemmas (e.g. names 
of patients, cities, pharmacies, pharmacists or physicians) 
were removed.
Methods
Study design and setting
Pharmacists wrote a narrative of a moral dilemma they had 
experienced in clinical practice, as an assignment during 
either pre- or postgraduate training. The pharmacists were 
asked to write this narrative immediately after they had 
experienced the dilemma. A stratified random sample of 
these narratives was taken. All pharmacists had been taught 
how to recognise moral dilemmas. This study followed sci-
entific standards for reporting qualitative research (SRQR; 
see “Appendix”) [42, 43].
Definition of moral dilemmas
On the basis of the various definitions in the literature [25, 
29, 35, 40, 44, 45], a ‘moral dilemma’ was defined as: a situ-
ation in which there is a choice between at least two courses 
of action, neither of which is obviously morally preferable. 
Narratives were checked against this working definition by 
both the first author (MK) and a member of an expert panel 
consisting of eleven senior pharmacists active in the spe-
cial interest group on pharmacy ethics of the Royal Dutch 
Pharmacists Association. All panellists had been trained in 
a half-day ethics course to identify moral dilemmas. If con-
sensus was not reached, a third pharmacist from the research 
group (WG, MB or AF) was consulted. Narratives that did 
not comply with our working definition were excluded.
Data analysis
Inductive content analysis of narratives to identify themes 
of moral dilemmas was facilitated with ATLAS.ti (ver-
sion 7.5.17) [46]. Consensus on final themes and main 
categories was reached in two rounds, during independent 
validation by the research group and during a consensus 
meeting with both the expert panel and research group.
Results
Of the 220 narratives, 92 were excluded (Fig.  1). The 
included 128 narratives were written by pregraduates (49%: 
51% male, 49% female) and postgraduates (51%: 39% male, 
61% female). Twenty-two themes were identified, divided 
into three main categories (see Table 1). Below, we illustrate 
the themes with a brief summary of a dilemma and quotes 
from pharmacists that reflect the essence of the theme.
N = 220 Narraves
128  Complied to the 
working definion* 
of a moral dilemma
59 Excluded
• Did not comply with the working definion* 
or were unclearly wrien 
33 Excluded 
• 22 Not a community pharmacy perspecve
• 10 Not coded by one panellist
• 1   Double 
187 Eligible 
Fig. 1  Inclusion of narratives. *A situation in which there is a choice 
between at least two courses of actions, neither of which is obviously 
morally preferable
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Category 1: The pharmacist–patient relationship
Drug abuse or addiction
Patients who had (or were suspected to have) drug abuse 
or addiction problems requested for refills too soon. The 
drugs involved were mainly controlled drugs such as opi-
oids or benzodiazepines. Pharmacists grappled with the 
problem of possibly sustaining addictive behaviour on 
the one hand and the need to retain patients’ trust and to 
relieve pain or anxiety on the other.
PHARM-276: This patient is heavily addicted to an 
opiate and regularly asks for, and gets, a refill too 
early. “He always has excuses like ‘I carried a heavy 
load yesterday’ or ‘I lost my medication during holi-
days’. However, he does experience pain and needs 
an analgesic. If he needs the opiate because he has 
really lost it, he should get it. But how long should 
I contribute to his opiate addiction.”
Drug misuse
Drug misuse can lead to side effects or affect the effective-
ness of the prescribed medicine. Pharmacists expressed con-
cern about confronting patients without losing their trust. 
Dispensing without addressing the issue also had drawbacks.
PHARM-1082: The pharmacist is aware that a student 
has been collecting methylphenidate only twice a year 
(coinciding with exams in January and June). The 
prescriber is the patient’s father. “Should I cooperate, 
give priority to the patient’s autonomy and dispense 
this medicine when I doubt whether the drug is actu-
ally indicated for a ‘chronic’ illness? Or do I need to 
address this presumed off-label use?”
Deviating treatment preference
Patient treatment preferences might not be supported by 
evidence-based medicine or professional guidelines. In these 
Table 1  Themes of moral 
dilemmas experienced by 
community pharmacists in 
clinical practice (N = 128)
a In this study dentists were also grouped as physicians
Category 1: The pharmacist–patient relationship n = 59
• Drug abuse or addiction 10
• Drug misuse 6
• Deviating treatment preference 10
• Claiming and/or aggressive behaviour 7
• Medication understanding 6
• Patient’s privacy 6
• Sharing relevant patient data with health professionals 5
• Public health policy and third-party payer regulations 9
Category 2: The pharmacist-colleague relationship n = 35
• Disruptive behaviour of a  physiciana 9
• Disruptive behaviour of a colleague 5
• Pharmacist and physician have a different opinion about appropriate pharmacotherapy 7
• A troubled relationship with the physician 4
• Deviating from a prescription with the  physiciana absent 3
• Missing relevant patient data with the  physiciana absent 3
• Loyalty conflicts 3
• Physician’sa self-prescribing 1
Category 3: Various relationships or involved parties n = 34
• Reimbursement for a pharmaceutical product or pharmaceutical care 9
• Risk of harm to children 7
• Risk to the unborn child 5
• End-of-life pharmaceutical care 6
• Dispensing without a prescription 5
• Quality defects 2
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situations, the pharmacists considered patients’ preferences 
potentially ineffective or harmful. 
PHARM-1235: A mother requested paracetamol for 
her 1-year-old baby who had a high fever for a week. 
“I tried to convince her to consult her GP as her baby 
might have a dangerous infection. She didn’t agree. 
Her attitude frustrated me. I want to do what is best 
for the baby, but at the same time have to respect the 
mother’s decision.”
Claiming and/or aggressive behaviour
Claiming or aggressive behaviour of patients undermines 
the trust-based relationship pharmacists have with patients 
and frustrates pharmacists because it might prevent them 
from providing adequate care. This is a complex situation, 
especially if there are other patients waiting in the pharmacy.
PHARM-1062: A patient asked the pharmacist for a 
prescription of oxazepam that had been faxed 2 months 
ago. The electronic patient record, however, suggested 
that the prescription had already been dispensed. 
The patient became furious and insisted that he had 
never received the drug and needed it urgently. “I felt 
attacked, but also had my doubts because of his con-
vincing manner of speaking. Did we make a mistake? 
Should I dispense once again without a prescription?”
Medication understanding
Patients (or their carers) who had difficulties understanding 
drug information because of language deficiency or limited 
health literacy, posed a particular problem. Pharmacists 
doubted whether these patients would use the drug safely, 
but not dispensing was not an option if the patient clearly 
needed treatment.
PHARM-314: An elderly Spanish speaking patient 
did not understand the pharmacist who explained 
the need for gastroprotection during NSAID use. She 
kept repeating that she was in pain and only needed 
the NSAID. This situation did not change even with 
a translator. “I wanted to assist and advise her cor-
rectly but poor communication made that impossible. 
I had my doubts about dispensing the NSAID without 
gastroprotection because of the possible health risks.”
Patient’s privacy/sharing relevant patient data
Sharing patient data with either health professionals or 
informal carers may be necessary from a clinical perspec-
tive. Dilemmas occurred when the pharmacist felt a need to 
share data, but patient’s consent to share data was absent or 
patients even requested not to share these data.
PHARM-252: A woman treated for a bipolar disor-
der told her pharmacist that she wanted to discontinue 
mirtazapine. She explicitly asked the pharmacist not 
to notify her psychiatrist. “I explained to her that I 
couldn’t provide proper pharmaceutical counselling 
because I didn’t have relevant background informa-
tion.” Although the pharmacist wanted to respect her 
autonomy, he also felt he should notify the psychiatrist.
Public health policy and third‑party payer regulations
In general, current health policy is directed at curbing 
increasing health expenditure. Dutch health insurance com-
panies reimburse only generic products unless the physi-
cian has medical reasons for prescribing a branded drug. 
While pharmacists recognised their responsibility to reduce 
health expenditure, this also disturbed their relationship with 
patients who strongly objected to generics.
PHARM-84: A patient, objected strongly to generic 
salbutamol. “After persistently trying to explain the 
drug reimbursement policy to him, I convinced him to 
try the generic for at least 14 days. A few hours later, 
he reported numerous complaints. Later the patient 
came with a prescription for the branded aerosol and 
a statement from his physician declaring the necessity 
of him having the original drug. Somehow, I felt the 
patient had never really tried the generic.” The phar-
macist had doubts about whether he should start the 
conversation with the patient again or fill the prescrip-
tion.
Category 2: The pharmacist–colleague relationship
Disruptive behaviour of a physician/a troubled relationship 
with the physician
Pharmacists described situations in which the relationship 
with physicians was troubled. Sometimes physicians even 
behaved disruptively e.g. by not listening to the pharmacists’ 
pharmacotherapy suggestions. This deprived the pharma-
cists of relevant information and caused frustration because 
their expertise was not appreciated. Pharmacists had reser-
vations about the safety or effectiveness of prescribed treat-
ment. Not dispensing, however, was equally problematic 
because reasons for the chosen treatment might have been 
valid. Moreover, pharmacists were anxious to further disrupt 
their professional relationship with the physician.
PHARM-54: A cardiologist deviated from the guide-
line for combining antiplatelet drugs. When the 
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pharmacist requested clarification, the cardiologist’s 
replied: “Do you mind if I continue with my patients 
now?” The pharmacist could not properly inform the 
patient about his doubts about the therapy. “I had 
strong doubts about the safety of this combination. 
Informing the patient about the risks, however, might 
worry the patient and undermine his confidence in the 
cardiologist.”
Disruptive behaviour of a colleague
Pharmacists reported disruptive behaviour of colleagues, 
such as gossip, lying or suspected fraud. Both neglecting and 
addressing such behaviour could influence the work climate 
in the pharmacy.
PHARM-1084: A pharmacy is reimbursed for every 
patient who receives instructions about a new inhaler. The 
senior pharmacist asked a junior pharmacist to send a list of 
all patients who had received a new inhaler with instructions 
to the insurance company for reimbursement. The junior 
pharmacist was reluctant to do this, struggling with going 
against his senior colleague’s request as well as his respon-
sibility to society. “I was uncertain whether the instructions 
had always been given. Technicians didn’t always document 
this and patients sometimes refused the instructions or had 
already received them elsewhere.”
Pharmacist and physician have a different opinion 
about appropriate pharmacotherapy
In these dilemmas physicians ‘overruled’ pharmacists’ 
proposals, although not necessarily in a brusque manner. 
Pharmacists had the idea that the physician did not really 
consider their suggestions and doubted the suboptimal or 
unsafe pharmacotherapy. Pharmacists felt at a disadvantage 
because they lacked sufficient knowledge about the patient’s 
condition. Moreover pharmacists did not want to further dis-
rupt their professional relationship with the physician.
PHARM-22: The pharmacist had suggestions about 
alternative therapy options for a patient with serious 
pain complaints. However, the physician said that he 
had tried everything and that nothing more could be 
done and did not want to change the medication. “In 
the end, it is the physician who prescribes. I wanted to 
help the patient but suggesting these options directly 
to the patient also did not feel appropriate.”
Deviating from a prescription or missing relevant data 
with the physician absent
Pharmacists had a moral dilemma when they wanted to devi-
ate from a prescription because of potential drug related 
problems such as interactions or allergy warnings, or to dis-
cuss the treatment because lack of relevant clinical data, but 
could not contact prescribers. Both situations impeded their 
judgement on the appropriateness of pharmacotherapy.
PHARM-350: A dentist prescribed amoxicillin. The 
pharmacist knew that the patient had previously had an 
allergic reaction on amoxicillin. The dentist could not 
be reached, but the patient urgently needed medication. 
“What if the dentist does not agree with the alternative 
antibiotic clindamycin?
Loyalty conflicts
Pharmacists had a conflict of loyalty when their decisions 
would either affect their professional relationship with col-
leagues or result in suboptimal patient care.
PHARM-115: A physician asked the pharmacist to 
urgently prepare a midazolam infusion to start pallia-
tive sedation for a patient registered at a neighbouring 
pharmacy. The physician explained that the pharma-
cist of that pharmacy was not able to prepare the infu-
sion that day. “In my opinion not dispensing wasn’t an 
option because of the condition of the patient. On the 
other hand, I didn’t want to overrule the decision of my 
colleague-pharmacist who is the responsible profes-
sional for this patient.”
Physician’s self‑prescribing
Although this is a well-known issue [47], only one case of 
physician self-prescribing was reported:
PHARM-1176: A physician prescribed midazolam for 
himself. “Dispensing felt problematic because sleep 
medication might have negative effects on the phy-
sician’s daily functioning. Moreover, the pharmacist 
did not want to become the accomplice of an addicted 
physician. However, not dispensing could damage the 
professional relationship and future collaboration.
Category 3: Various relationships or involved parties
The previous categories of dilemmas involved patients or 
health professionals. In the following themes other ‘stake-
holders’ were involved, such as health insurance compa-
nies and manufacturers. We also included dilemmas with 
(unborn) children and adolescents in this category, as phar-
macists in these situations have a complex responsibility 
towards these unborn children, minors and their parent(s) 
or legal representatives.
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Reimbursement for a pharmaceutical product/care activity 
or additional service
Pharmacists experienced dilemmas when patients were not 
insured and not able to pay their medication out of pocket, 
because these patients needed their medicines. Also, con-
cerns about pharmacy workload sometimes conflicted with 
pharmacists’ wish to deliver optimal but time-consuming 
patient care. Providing additional services for some patients 
would mean compromising on other services.
PHARM-278: A nursing home requested multidose 
drug dispensing systems for every patient. This would 
include anticoagulant medication, the dosing of which 
often has to be adjusted. The pharmacy did not have 
the capacity to change the multidose drug dispensing 
systems manually each week. “I realise the importance 
of this request, but it would almost take an extra tech-
nician without getting any reimbursement.”
Risk of harm to (unborn) children
Pharmacists confronted with off-label prescriptions for chil-
dren and adolescents felt they could not appropriately assess 
the risk–benefit ratio or the correct dosing of drugs. Another 
dilemma was when children collected medication. Pharma-
cists worried about the possibility of the child misusing the 
medication, but also did not want the patient to be left with-
out medication. Even more complicated moral dilemmas 
arose when medication was prescribed to pregnant women. 
In these cases, pharmacists had to weigh the benefits for the 
mother against the potential risks for the unborn child.
PHARM-1202: “A psychiatrist told me he did not 
want to tell a pregnant woman with a major depres-
sive disorder about the teratogenic risks of paroxetine 
because he was afraid that she would not take the drug. 
The psychiatrist considered that the mother not taking 
paroxetine would potentially be riskier for the unborn 
child than the small teratogenic risk. I struggled with 
appropriate counselling.”
End‑of‑life pharmaceutical care
These dilemmas concern euthanasia or palliative sedation. 
Dutch Pharmacists’ and Physicians’ Associations have a 
joint guideline on providing euthanasia [48]. Sometimes 
physicians did not adhere to the guideline recommendations; 
e.g. a physician requested euthanasia drugs without timely 
communication with the pharmacist. Pharmacists were then 
reluctant to cooperate. However not dispensing felt wrong 
because the patient was suffering.
The dilemmas that dealt with palliative sedation con-
cerned both disagreement about the dose of palliative 
sedation and the expectations of physicians that pharmacists 
would have the necessary drugs readily available.
PHARM-57: This pharmacist did not dispense drugs 
for euthanasia because of religious objections. Sur-
rounding physicians knew about this. A physician from 
another area, unaware of the objections, requested 
these drugs too late in the day to find another phar-
macist. “Should I remain faithful to my personal val-
ues but then trouble both the patient and physician, or 
should I dispense the drugs this one time?”
Dispensing without a prescription
Patients regularly requested (restricted) medicines without a 
(valid) prescription. In these situations, pharmacists had to 
balance the necessity and risks of dispensing. Pharmacists 
felt it hard to make this balance because they had insufficient 
clinical information and were reluctant to deviate from laws 
and regulations.
PHARM-71: The middle-aged son of an elderly patient 
visited the pharmacy just before closing time. He 
showed a picture on his mobile phone of an oxyco-
done prescription for his father who had just been dis-
charged from hospital. He said his father suffered from 
severe pain and he could not get the real prescription 
in time before the pharmacy closed. “The prescription 
does not comply with the law but this patient could 
suffer unnecessarily if I don’t dispense.”
Quality defects
These moral dilemmas were related to uncertainty about the 
quality of a pharmaceutical product and the risks of dispens-
ing a product that might be ineffective or harm patients.
PHARM-309: A patient visited the pharmacy with 
three golimumab injections worth €3500 which had 
been outside the refrigerator for about 1 day. “The 
manufacturer told me they expected no quality issues 
but could not give any guarantee.” The pharmacist 
doubted whether the patient would be harmed by using 
the injections, and felt that, given their cost, discarding 
the injections was not socially responsible.
Discussion
This study presents moral dilemmas experienced by commu-
nity pharmacists in clinical practice. The underlying themes 
address the challenges pharmacists face while providing care 
in a complex setting with economic and legal constraints, 
demanding patients and limited professional autonomy. 
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Analysis showed that most moral dilemmas concerned 
the relationship between pharmacists, patients and physi-
cians. This is not surprising considering that pharmacists 
are responsible for helping patients achieve positive health 
outcomes, and this responsibility requires that they work 
with patients and other health professionals [49].
As far as we know, no previous study used narratives to 
understand the moral dilemmas that pharmacists experience 
in clinical practice [26, 29, 40]. Writing a narrative shortly 
after a dilemma occurred avoids recall problems and enables 
pharmacists to reflect directly on their feelings. Previous 
studies generally interviewed pharmacists and asked them 
to recall dilemmas that occurred in the past [29, 40]. This 
may be the reason why, in those studies, pharmacists mainly 
recalled dilemmas with a high legal impact. For example, 
pharmacists expressed fear of breaking the law when a 
patient asked for a controlled drug without a (valid) pre-
scription [26, 29, 40]. When legal issues occurred in this 
study, pharmacists were more concerned about the patient’s 
well-being and the mutual trust in the treatment relationship 
than about breaking the law.
Pharmacists experienced dilemmas during their profes-
sional contacts because the behaviour of patients and physi-
cians made it difficult for them to act autonomously, accord-
ing to their professional core values [50]. Since the days of 
Hippocrates, health professionals’ core value is not to harm 
patients and to act in their best interest. However, conflicts 
may arise when more than one health professional aims 
to act according to that value. The degree of professional 
autonomy of an individual health professional depends on 
the extent to which other health professionals grant that 
autonomy [51]. Regular collaboration between pharmacists 
and other health professionals may promote mutual trust and 
respect for each other’s knowledge and expertise [52–54].
Pharmacists’ autonomy may also be challenged because 
pharmacists are often the last link in a multidisciplinary care 
chain, e.g. in end-of-life pharmaceutical care issues. In that 
position pharmacists’ expertise comes into play too late or 
is not recognised [55, 56]. Pharmacists in these situations 
described that their expertise was disregarded and that they 
were expected to dispense only. These moral dilemmas dem-
onstrate that pharmacists need more training to convince 
physicians of their expertise.
The professional autonomy of pharmacists may also be 
restricted by patients or parties such as insurance compa-
nies or the health inspectorate. Patients may also consider 
physicians to have more authority than pharmacists. This 
can sometimes lead to claiming and/or aggressive behaviour 
of patients. This behaviour undermines the trust relation-
ship between the pharmacist and the patient. This resembles 
healthcare consumerism, which is reported to challenge the 
ability of health professionals to optimally fulfil patients’ 
and societal needs [9–14]. Dilemmas under the theme public 
health policy and third-party payer regulations showed 
that health insurance companies can also undermine phar-
macists’ autonomous professional decision-making and 
actions. Insurance companies oblige pharmacists to replace 
expensive branded drugs with cheaper generics. Although 
pharmacists do not object to dispensing cheaper medicines 
whenever possible, this responsibility also disturbed their 
relationship with patients who strongly objected to gener-
ics. This finding confirms a worldwide trend that economi-
cally motivated health policies challenge the professional 
autonomy of all health professionals [12–14, 17, 18]. Health 
policy makers should realise that weakening health profes-
sionals’ autonomy, for example due to reimbursement poli-
cies, may negatively affect patients’ trust in health care [19].
Limitations
This study has some limitations. Firstly, the moral dilemmas 
were reported by ‘early career’ pharmacists. These phar-
macists may be more committed to patients’ well-being, 
because of more advanced training on the patient perspec-
tive than earlier generations of pharmacists. Moreover, the 
training provided might have influenced their sensitivity 
for moral dilemmas [57]. The themes underlying the moral 
dilemmas were not less numerous than those in previous 
studies involving more experienced pharmacists. Exceptions 
to this are primary business dilemmas. The underreporting 
of these types of dilemmas might be explained by the fact 
that the early career pharmacists in our study generally do 
not own a pharmacy. A second limitation is that saturation 
of themes was not formally assessed. We did, however, 
have no clues on additional themes from the excluded nar-
ratives. Moreover, screening of an additional stratified ran-
dom sample of 50 narratives by two authors (MK and MB) 
neither gave clues on missed themes. Therefore, we are of 
the opinion that the most important themes for the Dutch 
context are identified. This does, however, not imply that 
every individual pharmacist will identify these dilemmas. 
Furthermore, our results are not completely generalizable 
to countries with different health systems and a different 
position of the community pharmacist in health care. Lastly, 
the written narratives contained much richer information 
than reported in our brief summaries; some narratives were 
excluded because they were unclear. As we were primarily 
interested in the themes, we did not analyse the feelings of 
pharmacists in depth.
Implications for practice
This study suggests that a short training enables pharmacists 
to write narratives on moral dilemmas they experience in 
clinical practice. Reflecting on these dilemmas may help 
pharmacists to increase their professionalism. Hence, we 
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suggest to integrate such ethical training in experiential 
learning within both pre- and postgraduate education. This 
will raise pharmacists’ awareness on moral conflicts and will 
support the profession’s transition to delivering pharmaceu-
tical care.
Conclusion
Pharmacists experience a number of moral dilemmas in 
clinical practice. The narrative method enables pharmacists 
to reflect directly on their feelings at the time these dilem-
mas occur. Most dilemmas involve the pharmacists’ profes-
sional relationships and often arise when the professional 
autonomy of pharmacists is challenged by patients’ and 
other health professionals’ behaviour.
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Appendix: Standards for reporting 
qualitative research [42, 43]
Topic Check Remarks
Title X
Abstract X
Introduction
Problem formulation X Included in ‘Introduction’
Purpose or research question X Included in ‘Introduction’
Methods
Topic Check Remarks
Qualitative approach and 
research paradigm
X Narrative research. Inductive 
formulation of themes. The 
research paradigm was inter-
pretivist/constructivist [43] 
as predominantly qualita-
tive techniques were used 
to formulate themes (see 
‘Definition of moral dilem-
mas’ and ‘Data analysis’). 
Rationale for the qualitative 
approach was the aim to find 
themes of moral dilemmas 
within written narratives
Researcher characteristics 
and reflexivity
X Panellists and the research 
team were all experienced 
pharmacists and trained in 
a half-day ethics course to 
identify moral dilemmas. 
The first researcher is a soci-
ologist with a pre-master in 
applied ethics and 12 years 
work experience in phar-
macy practice research
Context X The participating pharma-
cists wrote their narratives 
as an assignment during 
either pre- or postgraduate 
training. They consented to 
the use of their narratives 
for research purposes. Only 
these written narratives were 
selected and analysed. See 
‘Study design and setting’
Sampling strategy X Included in ‘Study design and 
setting’
Ethical issues pertaining to 
human subjects
X Included in ‘Ethics approval’
Data collection methods X The narratives were written by 
the participating pharma-
cists as an assignment dur-
ing either pre- or postgradu-
ate training
Data collection instruments 
and technologies
Not relevant as the participat-
ing pharmacists wrote the 
narratives used
Units of study X Early career pharmacists
Data processing X Included in ‘Ethics approval’ 
and ‘Data analysis’
Data analysis X Qualitative content analysis 
was used to identify themes 
(see ‘Data analysis’)
Techniques to enhance 
trustworthiness
X Included in ‘Definition of 
moral dilemmas’, ‘Data 
analysis’ and ‘Limitations’
Results/findings
Synthesis and interpretation X Included in ‘Results’ and 
‘Discussion’
Links to empirical data X Included in ‘Results’ and 
‘Discussion’
Discussion
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Topic Check Remarks
Integration with prior work, 
implications, transferabil-
ity, and contribution(s) to 
the field
X Included in ‘Discussion’ and 
‘Implications for practice’
Limitations X Included in ‘Discussion’
Other
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